SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Ada Lovelace

PatientAda Lovelace
Date of birth1990-12-10
IdentifiersMRN HR-NI031-SYN; SSN (made up) 000-31-6729
Document date2026-07-14
AuthorConstance Whitley-Adeyemi, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review: bleeding and pain after palliative pelvic radiation, two weeks after the first cycle of chemotherapy with pembrolizumab. [S]

History of Present Illness

Mrs. Lovelace returns four weeks after the consultation. The lung biopsy three weeks ago confirmed metastatic adenocarcinoma matching the cervical tumor. She completed five days of pelvic radiation, and the bleeding stopped within a week. She had the first cycle of carboplatin, paclitaxel and pembrolizumab two weeks ago, with nausea for two days. The constipation that brought her in a week ago settled within two days of the extra laxatives. Her average pelvic pain is 3 of 10 on long-acting morphine 15 mg twice a day, with a breakthrough dose on some days, and she is clear-headed in the mornings and working again. She feels low at times and finds it hard to sleep the night before treatment. She has no rash, diarrhea, or cough. [S]

ElementDetail
BleedingStopped a week after radiation
PainAverage 3 of 10; breakthrough dose on some days; clear-headed
ChemotherapyFirst cycle two weeks ago; nausea for two days
BowelsRegular again since the sick visit
MoodLow at times; PHQ-9 9

Review of Systems

SystemResultFinding
GenitourinaryNegativeNo bleeding; light discharge; no urinary burning
GastrointestinalNegativeBowels regular; no diarrhea
IntegumentaryNegativeNo rash
RespiratoryNegativeNo cough or breathlessness
PsychiatricPositiveLow at times; poor sleep before treatment; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain0.5 mL four to six times a day as neededOral route2024-06-03 to 2026-06-02completedS
Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain5 mg every 4 hours as neededOral route2026-06-02activeS
Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow wholeevery 12 hoursOral route2026-06-16 to 2026-10-20completedS
Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911one spray as needed for suspected overdose; repeat after 2 to 3 minutes if neededNasal route2026-06-02activeS
Senna 8.6 mg tablet, two tablets by mouth at nighttwo tablets at nightOral route2026-06-02activeS
Polyethylene glycol 3350, 17 g in water by mouth once or twice a dayonce daily, up to twice dailyOral route2026-06-02activeS
Acetaminophen 500 mg tablet, two tablets by mouth three times a day1 g three times a dayOral route2026-06-02activeS
Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits750 mg on two occasions two weeks apartIntravenous route2026-06-02 to 2026-06-17completedS
Pembrolizumab 200 mg intravenously every 3 weeksevery 3 weeksIntravenous route2026-06-30activeS
Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cyclesevery 3 weeks for six cyclesIntravenous route2026-06-30 to 2026-10-13completedS
Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedicationevery 3 weeks for six cyclesIntravenous route2026-06-30 to 2026-10-13completedS
Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as neededtwice a day for three days after each cycle, then as neededOral route2026-06-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-14Body height165cmS
2026-07-14Body weight53.4kgS
2026-07-14Body mass index (BMI) [Ratio]19.6kg/m2S
2026-07-14Systolic blood pressure110mm[Hg]S
2026-07-14Diastolic blood pressure70mm[Hg]S
2026-07-14Heart rate84/minS
2026-07-14Respiratory rate16/minS
2026-07-14Body temperature36.6CelS
2026-07-14Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-14Hemoglobin [Mass/volume] in Blood9.8g/dL12-15.5 g/dLLowS
2026-07-14Leukocytes [#/volume] in Blood by Automated count4.110*3/uL4-11 10*3/uLNormalS
2026-07-14Neutrophils [#/volume] in Blood by Automated count2.210*3/uL1.8-7.7 10*3/uLNormalS
2026-07-14Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS
2026-07-14Creatinine [Mass/volume] in Serum or Plasma0.7mg/dL0.57-1 mg/dLNormalS
2026-07-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-07-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M116mL/min/{1.73_m2}60 or moreNormalS
2026-07-14Pain severity - 0-10 verbal numeric rating [Score] - Reported3{score}S
2026-07-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S

Physical Exam

Vital signs recorded on 2026-07-14; see the Vital Signs section. [S]

SystemFinding
GeneralAlert, not sedated; blood pressure 110/70, pulse 84, weight 53.4 kg
MouthNo mucositis
AbdomenSoft; mild suprapubic tenderness
NeurologicalSensation normal in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intakeresolvedconfirmed N93.8S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairsactiveconfirmed D50.0S — Synthetic modern finding anchored to her documented final illness.
Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosisactiveconfirmed C53.0S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice.
Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extensionactiveconfirmed G89.3S — Synthetic modern diagnosis made at the second visit.
Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone suppliedactiveconfirmed Z79.891S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing.
Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxativesresolvedconfirmed K59.03S — Synthetic adverse drug effect; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count (hemoglobin, white cells, neutrophils, platelets)Before each chemotherapy cycle and at each visitCompleted todayHemoglobin 9.8 g/dL, white cells 4.1, neutrophils 2.2, platelets 236
LaboratoryCreatinine, eGFR and ALTBefore each cycleCompleted todayCreatinine 0.70 mg/dL, eGFR 116, ALT 22 U/L
LaboratoryTSH and free T4 on pembrolizumabBaseline, then every 6 weeksDueBaseline four weeks ago; next due in two weeks, six weeks from baseline
LaboratoryFerritin after intravenous iron6 to 8 weeks after the infusionsDueDue in two to four weeks
ExaminationVaginal bleeding and transfusion needEvery visitCompleted todayNo bleeding since radiation
ExaminationImmune-related adverse effects: rash, diarrhea, cough, fatigueEvery visitCompleted todayNone
ExaminationPeripheral neuropathy on paclitaxelBefore each paclitaxel cycleCompleted todayNone
ImagingRestaging CT of chest, abdomen and pelvisEvery 2 to 3 cycles during first-line therapy, then every 3 monthsDueAfter four cycles
SurveyPain intensity (0 to 10) and functionEvery visitCompleted todayAverage 3 of 10
Medication safetyOpioid adverse effects: sedation, confusion, nauseaEvery visitCompleted todayNo sedation; nausea for two days after the cycle
Medication safetyBowel regimen and constipationEvery visitCompleted todayConstipation a week ago, resolved; daily laxatives
Medication safetyNaloxone, locked storage, one prescriber, prescription monitoring checkAt each opioid change, and every 3 monthsUp to dateNaloxone at home; locked storage
Medication safetySigns of opioid use disorderEvery visitCompleted todayNone
SurveyDepression screen (PHQ-9) and distressAt diagnosis and periodicallyCompleted todayPHQ-9 9, mild; offered and accepted psycho-oncology counseling
ReferralSpecialist palliative careOngoing alongside cancer treatmentCompleted todaySeen twice by the palliative care team

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021); Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021)

Follow-up: Second cycle next week. Preventive visit in five weeks. Fourteen-week review after the restaging CT. Next scheduled visit 2026-08-18: periodic adult preventive visit. [S]